326 related articles for article (PubMed ID: 28680105)
1. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
[TBL] [Abstract][Full Text] [Related]
2. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
3. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
4. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
[TBL] [Abstract][Full Text] [Related]
5. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
6. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract][Full Text] [Related]
7. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
[TBL] [Abstract][Full Text] [Related]
8. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.
Eloy C; Santos J; Soares P; Sobrinho-Simões M
Virchows Arch; 2011 Sep; 459(3):265-76. PubMed ID: 21796448
[TBL] [Abstract][Full Text] [Related]
9. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
10. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
12. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
13. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
14. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
15. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
16. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
Vasko V; Hu S; Wu G; Xing JC; Larin A; Savchenko V; Trink B; Xing M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5265-9. PubMed ID: 15998781
[TBL] [Abstract][Full Text] [Related]
17. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
18. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of BRAF and NRAS mutations in thyroid tumors in patients from Argentina].
Repetto EM; Fernandez L; Lambertini R; Del Valle Jaen A; Ruda Vega V; Moldes S; Lutfi R; Aranda C; Faure E; Oneto A
Medicina (B Aires); 2023; 83(4):505-513. PubMed ID: 37582124
[TBL] [Abstract][Full Text] [Related]
20. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
